Children with autism spectrum disorder (ASD) and attention deficit-hyperactivity disorder (ADHD) had improvements in their symptoms with a liquid formulation of methylphenidate (Quillivant), researchers reported here. In preliminary findings from a small trial, patients given the drug had significant improvement in Clinical Global Impression (CGI) scores after 6 weeks compared with baseline, reported Mark Stein, PhD, of Seattle Children's Hospital, and colleagues reported at the American Professional Society of ADHD and Related Disorders (APSARD) meeting.